JS-007 Drug Asset Due Diligence Report 2026

This JS-007 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether JS-007 can convert its Monoclonal antibody profile and CTLA4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	JS-007 (query alias: JS-007)
Modality / target	Monoclonal antibody; CTLA4; CTLA4 inhibitors
Highest global status	Phase 2
Originator	Shanghai Junshi Biosciences Co., Ltd.
Active developers	Shanghai Junshi Biosciences Co., Ltd.

The MCP disease footprint includes Advanced Hepatocellular Carcinoma, Neoplasms, Advanced Malignant Solid Neoplasm. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20263532	Phase 3	Not yet recruiting	560	Primary endpoint not disclosed in English source
NCT06954467	Phase 2	Recruiting	72	Primary endpoint not disclosed in English source
CTR20251351	Phase 2	Active, not recruiting	72	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors

Not disclosed; n=28; evaluation: Not stated in English source. Reported fields: mOS = 14.7 Month

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

JS-007 addresses Advanced Hepatocellular Carcinoma, Neoplasms, Advanced Malignant Solid Neoplasm. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 63 matched transaction record(s) under the scope “target-level comparable: CTLA4.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CTLA4 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-04-28	China’s BeOne Eyes Global Rights to Huahui Health’s Pre-Clinical Cancer Therapy	Preclinical	US$20.0M upfront; US$1,974.0M milestones
2026-02-22	Harbour BioMed Announces License Agreement and Equity Partnership for a Clinical Stage Antibody	Phase 2	US$50.0M upfront; US$1,100.0M milestones
2026-01-06	Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco	Phase 1/2	US$50.0M upfront; US$2,000.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Gene signatures predictive of cancer cell response to immunomodulatory therapy”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition of Anti-CTLA-4 antibody and use thereof”. The milestone feed surfaced a patent-application signal described as “Anti-CTLA-4 antibody and use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO